Lv11
20 积分 2023-12-19 加入
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
6小时前
待确认
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
3个月前
已完结
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
3个月前
已完结
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
1年前
已完结
皖公网安备34019202002308
